Santaris Pharma A/S

Upon a successful double track process with full filing of F-1 at NASDAQ in New York while engaging in discussions with Roche (Switzerland), Sunstone closed an M&A transaction with Roche with a total volume of up to USD 450 million. Roche pays an upfront component of USD 250 million, and contingent components of up to USD 200 million relating to preclinical and clinical developments until August 1st, 2019. Sunstone represented 24% of the shares, and acted as all seller’s representative throughout the transaction. Santaris be renamed to Roche Innovation Center Copenhagen (RICC) and will stay in the current premises.

http://www.santaris.com
Claus Andersson

Partner

Mobile: +45 22 70 50 65
Email Click here to contact